A Trace ‘Tides Primer: Understanding a synthetic ACTH fragment analogue from Russian peptide research

By: Laura Mildon

Semax is a synthetic heptapeptide: a chain of seven amino acids joined by peptide bonds. Its sequence is methionine–glutamic acid–histidine–phenylalanine–proline–glycine–proline, abbreviated MEHFPGP. Its research history includes investigation of neurotrophic signaling and responses to experimental brain injury.

Although frequently mentioned alongside Selank, Semax is a different molecule with a different sequence and research lineage. Published findings do not establish a benefit or intended application for a commercial research material.

How Semax relates to ACTH

ACTH stands for adrenocorticotropic hormone. Semax contains the sequence corresponding to ACTH residues 4 through 7, Met-Glu-His-Phe, followed by Pro-Gly-Pro. It is therefore described structurally as ACTH 4–7 PGP.

Older publications also describe it as an ACTH 4–10 analogue. That describes its design relationship rather than an unchanged copy of the natural 4–10 sequence. The full ACTH hormone and Semax should not be treated as the same compound.

Chemical identity

These values describe the specified peptide entity. Salt counterions, hydration, and terminal modifications require separate identification. N-acetyl Semax, amidated Semax, and an acetate salt are not interchangeable chemical descriptions.

PubChem chemical identity and structure

FDA chemical comparison of Semax and Semax acetate

Why Semax and Selank are different

Both peptides contain seven residues and end in Pro-Gly-Pro. Semax begins with Met-Glu-His-Phe, derived from an ACTH fragment. Selank begins with Thr-Lys-Pro-Arg, the tuftsin sequence.

Sharing a short terminal sequence does not make their molecular interactions or biological effects equivalent. Evidence about one molecule, or about the terminal fragment alone, cannot automatically be transferred to the other.

History and research origins

Semax emerged from Russian research into regulatory peptides and ACTH-derived sequences. A 1997 publication by Ashmarin and colleagues summarized approximately 15 years of design and investigation, documenting an earlier development program.

That retrospective report is a historical milestone, rather than proof of an exact discovery or first-synthesis date. Semax is a designed synthetic analogue, not a peptide isolated unchanged from a natural source.

Ashmarin and colleagues 1997 Russian-language development report

Selected published research

Semax is not FDA-approved as a medicine. These selected original studies address molecular and preclinical questions; they do not establish a clinical benefit or authenticate a commercial research material.

BDNF in rat basal forebrain in 2006

Dolotov and colleagues investigated Semax binding and brain-derived neurotrophic factor, or BDNF, in rat basal forebrain. Their study reported increased BDNF protein levels in that experimental setting.

BDNF is a signaling protein involved in neuronal functions and plasticity. A change in its measured level does not, by itself, demonstrate better memory, improved mood, or another clinical outcome in people.

Original study in Journal of Neurochemistry 2006

BDNF and TrkB in the rat hippocampus in 2006

Dolotov and colleagues examined BDNF and its receptor TrkB in the rat hippocampus. They reported changes in protein levels, gene expression, and receptor phosphorylation after Semax exposure.

Phosphorylation adds a phosphate group to a protein and can alter signaling activity. These were molecular measurements in a rat brain region. They should not be summarized as proof that Semax improves human cognition or regenerates brain tissue.

Original study in Brain Research 2006

Gene expression after experimental ischemia in 2014

Medvedeva and colleagues used a rat model of focal cerebral ischemia, a restriction of blood supply to a defined brain area. They compared gene-expression patterns after Semax exposure with those in the ischemia comparison group.

The researchers reported changes involving immune and vascular processes. This study addresses responses in an experimental injury model; it does not establish prevention or treatment of stroke in people. Findings from the complete peptide also need to be distinguished from findings about shorter fragments.

Medvedeva and colleagues in BMC Genomics 2014

Molecular structure

The molecular formula counts atoms; the sequence specifies their order along the peptide chain. PubChem provides a two-dimensional chemical depiction of the identified compound. This connectivity diagram is not an experimentally established fixed three-dimensional shape.

What remains unresolved

Important questions include which molecular interactions explain specific responses, how reproducible those responses are across research groups, and how laboratory measurements relate to meaningful clinical outcomes.

The selected studies do not resolve long-term human safety or effectiveness. Increasing a neurotrophic marker is different from demonstrating a lasting functional improvement. Results also depend on the biological model and the exact material studied.

Clinical reports exist in the broader literature, but FDA’s 2026 assessment identified limitations in evidence and noted that clinical references did not clearly distinguish the free peptide from its acetate salt. Animal studies, molecular assays, and human clinical reports require separate appraisal.

Regulatory context

FDA’s 2026 compounding assessment states that neither Semax nor Semax acetate is a component of an FDA-approved drug. It also notes that Semax is a registered drug in Russia. Registration in one country does not establish approval in another or authenticate an independently supplied research preparation.

The assessment identifies concerns about chemical characterization and the available safety and effectiveness evidence. It was prepared for an advisory committee addressing compounding questions; a briefing document or committee recommendation is different from approval of a medicine.

Research labeling does not establish FDA approval, clinical safety, or permission for another intended use.

FDA assessment of Semax and Semax acetate 2026

Research and regulatory sources checked October 13, 2026.

DISCLAIMER: These statements are for research purposes only and have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Why choose Trace 'Tides? 

Because trust starts with real people, clear answers, and quality you can verify. We have a certified peptide specialist on staff, a phone number that connects you with a real human, and a physical location you can visit by appointment. Call or text us—we’re delighted to answer your questions and address your concerns. We also make checkout straightforward by accepting credit cards, without asking you to use cryptocurrency or connect your bank account to an unfamiliar payment app. And every peptide we sell is tested for purity and endotoxins by licensed U.S. laboratories, so you can choose your research peptides with confidence.